Targeting oxLDL for Psoriasis Relief
Wednesday November 27, 2019
Psoriasis is a common skin condition that speeds up the life cycle of skin cells, however, many people aren’t exactly sure what causes psoriasis. Psoriasis is a unique and chronic disease that often comes and goes. Psoriasis occurs when your immune system or T cells are out of balance or overactive. An overactive immune system sends faulty signals and the T cells mistake healthy cells for harmful ones, resulting in too much inflammation. For psoriasis patients, this means the body rapidly produces more skin cells than necessary. There is no current cure for psoriasis, only ways to manage symptoms or reduce inflammation.
There are several types of psoriasis, but the most common is plaque psoriasis. Plaque psoriasis is a chronic inflammatory skin disease that affects 3 percent of the population and is associated with serious commodities such as cancer, diabetes and heart disease. Traditional therapies designed to treat plaque psoriasis have serious side effects and can increase risk of infections and cancer.
Inflammation is a primary driver behind many fatal and life-threatening diseases, including plaque psoriasis. Abcentra is working on addressing the unmet needs in inflammatory diseases by treating the root cause of the inflammation, instead of just the symptoms of the disease. Studies have shown that oxidized low-density lipoprotein, or oxLDL, may be implicated in common, chronic conditions caused by inflammation such as cardiovascular disease, rheumatological diseases and cancer. By targeting oxLDL, Abcentra aims to bring new, safer and more effective treatment options to patients with inflammatory diseases.
Abcentra’s lead candidate, orticumab, is the first and only fully human monoclonal antibody of its kind targeting oxLDL. It is being developed to treat plaque psoriasis and accelerated atherosclerosis in patients with rheumatoid disease.
For our lead candidate, Abcentra has completed three clinical trials to date, demonstrating an excellent safety profile for orticumab and showing evidence of activity in humans. Two patients in a prior clinical study experienced remission of plaque psoriasis after treatment with orticumab. Additionally, with strong scientific support, orticumab has been featured in several peer-reviewed scientific publications. Targeted treatment of oxLDL can lead to minimal side effects with a fast and cost-effective proof of concept. Abcentra is using this groundbreaking and patent protected research to improve the lives of patients.
Abcentra aims to bring new, safer and more effective treatment options to patients with inflammatory diseases. For more information about Abcentra and our lead candidate, orticumab, explore our additional resources.